CIDeRplusGeneral Information:
| Id: | 6,594 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Homo sapiens | |
| female | |
| article | |
| Reference: | Giugliano D et al.(1993) Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women Diabetes Care 16: 1387-1390 [PMID: 8269798] |
Interaction Information:
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62926 |
drug/chemical compound decreases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62927 |
drug/chemical compound increases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62928 |
drug/chemical compound decreases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62930 |
drug/chemical compound increases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62932 |
drug/chemical compound increases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62934 |
drug/chemical compound increases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62935 |
drug/chemical compound increases_activity of phenotype decreased circulating fibrinogen level |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62937 |
drug/chemical compound increases_activity of |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. |
|
Formal Description Interaction-ID: 62938 |
drug/chemical compound increases_activity of phenotype |
| Drugbank entries | Show/Hide entries for Metformin |
| Comment | After 3 months of treatment with metformin, plasma norepinephrine concentrations decreased from a mean value of 398 to 321 ng/L. |
|
Formal Description Interaction-ID: 62939 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Metformin |